China’s exports to India rose sharply in early 2026, while Indian shipments to China also increased at a strong clip. The trade between the two countries crossed $91 billion, but India’s shortfall grew to $67 billion. New Delhi is pushing for greater access for its pharmaceuticals and IT products in the Chinese market.
Rising Volumes, Uneven Balance
The latest figures show a rush of goods moving both ways. Officials reported stronger Indian sales to China by percentage terms, even as Chinese exports to India rose by a larger value. The result is a wider gap.
“China’s exports to India grew significantly in early 2026. Indian exports to China also saw substantial percentage increases during this period.”
That simultaneous rise pushed bilateral trade past the $91 billion mark.
“Bilateral trade between the two nations reached over ninety-one billion dollars.”
Yet the ledger remains skewed. India’s deficit expanded to $67 billion, highlighting long-running structural differences in what each side sells and buys.
“India’s trade deficit with China widened to sixty-seven billion dollars.”
Background: A Persistent Gap
India and China are major partners in goods trade, with China supplying electronics, machinery, active pharmaceutical ingredients, chemicals, and capital goods to Indian factories and consumers. India has pushed to raise its own manufacturing share and diversify supply chains, but dependence on Chinese inputs remains significant in many sectors.
Over the past several years, India has promoted local production for electronics, pharmaceuticals, and renewables. It has also urged domestic firms to seek more overseas customers. Despite these steps, the trade shortfall with China has stayed large due to high-value imports and limited market access for Indian products that can scale in China.
Market Access Push: Pharma and IT in Focus
New Delhi is again pressing Beijing to open doors for two of its strength areas: generic medicines and digital services. India is one of the world’s largest suppliers of generic drugs and vaccines. Its IT services industry is a global exporter. Both face entry and regulatory hurdles in China.
“India seeks greater access for its pharmaceuticals and IT products to China.”
Industry executives argue that approvals for Indian drug makers take time and often stall. Service providers cite data rules, licensing requirements, and procurement barriers. Expanded access could lift Indian exports and chip away at the deficit.
What the Numbers Signal
The surge in trade signals strong demand on both sides. It also reflects supply chain normalization and steady industrial activity. But the widening gap points to a mismatch: India imports high-value goods and inputs, while its sales to China remain narrower in scope.
- Trade value: over $91 billion in early 2026.
- India’s deficit with China: $67 billion.
- Priority sectors: pharmaceuticals and IT products seeking access.
Economists say higher-value Indian exports could help. Better entry for drugs and services would raise receipts without a major change in import demand that supports local manufacturing.
Industry Impact and Policy Options
Manufacturers in India depend on Chinese machinery and parts. Sudden curbs could raise costs and slow investment. A market access strategy targets the other side of the ledger: push exports where India is competitive while keeping critical inputs flowing.
Possible steps include faster regulatory pathways for Indian drug approvals in China, pilot projects for cross-border digital services, and mutual recognition of some standards. Transparent procurement rules could help smaller firms bid on Chinese contracts.
For China, allowing more Indian medicines could lower healthcare costs and ease supply pressures. Opening space for IT and business services could support efficiency for Chinese companies, especially those seeking global customers.
What to Watch Next
Talks on regulatory approvals and data compliance will be key. Any move by Chinese authorities to clear Indian pharma applications in larger batches would be a signal. On services, test programs for cloud, cybersecurity audits, and data transfers could show progress.
For India, sustaining export growth to China while managing essential imports is the near-term task. A shift in the trade mix—more value-added exports and steady access to inputs—would narrow the gap without disrupting production at home.
Trade is growing. The question is whether market access in pharma and IT can convert that growth into a smaller deficit. If concrete steps emerge in 2026, the $67 billion gap could start to ease.